Drug Trial Radar · NCT07875933
Efficacy and Safety of JP-1366-based Triple Therapy in Helicobacter Pylori-positive Subjects
Last checked: Nov 19, 2026Latest source record: Oct 15, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
414
Planned (sponsor's estimate)
Start
Nov 1, 2026
Primary completion
Sep 6, 2028
Study completion Oct 6, 2028
Sponsor
- Lead sponsor
- Onconic Therapeutics Inc.Industry
- Sponsor type
- Industry
- First posted
- Oct 15, 2026
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 19 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study aims to evaluate the Efficacy and Safety of JP-1366-based Triple-Therapy in H. pylori-positive Subjects
Conditions
- H. Pylori Eradication Therapy
Interventions
JP-1366 20 mg, Lansoprazole 30 mg Placebo, Clarithromycin 500mg, Amoxicillin 1000mgDrug
Orally, twice daily
Lansoprazole 30mg, JP-1366 20 mg Placebo, Clarithromycin 500mg, Amoxicillin 1000mgDrug
Orally, twice daily
Primary outcomes
What the sponsor says the trial is designed to measure.
- H. pylori eradication rate after a minimum of 4 weeks from completion of Investigational product administrationTime frame: at least 4 weeks after completion of administration
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.